This review discusses Wixela™ Inhub™, a generic equivalent of Advair Diskus®, a fixed-dose combination of fluticasone propionate/salmeterol powder for oral inhalation for patients with asthma and chronic obstructive pulmonary disease (COPD).

Wixela Inhub gave in vitro performance comparable to Advair Diskus for all strengths and flow rates for both single actuation content and impactor-sized mass.

Compared with matched placebo, Wixela Inhub and Advair Diskus both demonstrated statistically significant improvements for forced expiratory volume in 1 s (FEV1).

Fluticasone propionate/salmeterol dose strengths for Wixela Inhub and Advair Diskus are comparable.

The bioequivalence demonstrated supports the use of Wixela Inhub and provides a treatment option for patients with asthma or COPD.